SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act Of 1934
May 4, 2012
Date of Report (Date of earliest event reported)
CADISTA HOLDINGS INC.
(Exact Name of Registrant as Specified in
|State of Delaware
|(State of Other Jurisdiction
||(Commission File Number)
||Identification Number) |
207 Kiley Drive
Salisbury, MD 21801
(Address of principal executive offices)
(Registrant’s telephone number, including
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|›||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|›||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)|
|›||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))|
|›||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))|
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On May 4, 2012, R. Sankaraiah, resigned as a director of
Cadista Holdings Inc. (the “Company”) and the Company’s wholly-owned subsidiary, Jubilant Cadista Pharmaceuticals
Inc. (“Cadista Pharmaceuticals”). Mr. Sankaraiah, in addition to being a member of our Board of Directors also served
as a member of our Audit Committee until his resignation. Mr. Sankaraiah’s resignation was not as a result of any disagreement
on any matter relating to our operations, policies or practices.
(d) On May 4, 2012, the Board of Directors of the Company and
Cadista Pharmaceuticals elected Kamal Mandan, the Company’s current Chief Financial Officer, to serve as a director of each
of the Company and Cadista Pharmaceuticals. Mr. Mandan will receive no compensation, in addition to the compensation he receives
as serving as our Chief Financial Officer, for serving as a director. Mr. Mandan was not elected to serve on any committee of the
Company’s or Cadista Pharmaceuticals’ Board of Directors.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
||CADISTA HOLDINGS INC.
||/s/ Kamal Mandan
||Chief Financial Officer
Date: May 9, 2012